The intellectual property provisions in the TPP or in the CETA are designed to set a common standard, and to ensure that in the area of pharmaceuticals, or any other area that's covered in that chapter. They're designed to set a common standard so that Canadian businesses that innovate can have confidence their innovations will be protected, and their rights will be enforced when they trade.
We heard the other day that Canadian companies are good at innovating, but they're not necessarily as good as they could be at commercializing those innovations, or trading in the commercialization of those innovations. Part of what trade agreements seek to do is to give innovators confidence when they're out there trading in the world that they're going to have some protections for their innovations. It's one part of a suite of tools that could be used, but it is the part that we are responsible for.